Table 1 Clinical characteristics and parameters
n = 209 | |||
|---|---|---|---|
Gender (male/female) | 108 / 101 | ||
Age (years) | 60.7 | ± | 1.0 |
BMI (kg/m2) | 27.5 | ± | 0.4 |
Systolic blood pressure (mmHg) | 116.6 | ± | 0.9 |
Diastolic blood pressure (mmHg) | 67.6 | ± | 0.7 |
Diabetic duration (years) | 13.0 | ± | 0.8 |
HbA1c (%) | 9.7 | ± | 0.1 |
Glucose at 0 min (mg/dl) | 122.2 | ± | 1.6 |
Glucose at 6 min (mg/dl) | 140.4 | ± | 1.6 |
ΔGlucose (mg/dl) | 18.2 | ± | 0.5 |
Serum CPR at 0 min (ng/ml) | 1.84 | ± | 0.08 |
Serum CPR at 6 min (ng/ml) | 3.56 | ± | 0.14 |
ΔCPR (ng/ml) | 1.72 | ± | 0.07 |
AST (IU/l) | 31.6 | ± | 1.8 |
ALT (IU/l) | 35.9 | ± | 2.6 |
Albumin (g/dl) | 3.97 | ± | 0.03 |
Cholinesterase (IU/l) | 340.4 | ± | 5.5 |
Total Bilirubin (mg/dl) | 0.80 | ± | 0.02 |
PT-INR | 0.99 | ± | 0.01 |
Total Cholesterol (mg/dl) | 186.5 | ± | 2.7 |
Triglyceride (mg/dl) | 146.1 | ± | 6.3 |
HDL-Cholesterol (mg/dl) | 44.1 | ± | 0.9 |
LDL-Cholesterol (mg/dl) | 116.7 | ± | 2.3 |
Apolipoprotein A−1 (mg/dl) | 124.1 | ± | 1.5 |
Apolipoprotein B (mg/dl) | 95.9 | ± | 1.5 |
Apolipoprotein E (mg/dl) | 4.5 | ± | 0.1 |
Lipoprotein (a) (mg/dl) | 20.7 | ± | 1.7 |
Free Fatty Acid (mEq/l) | 0.56 | ± | 0.02 |
Remnant Like Particle Cholesterol (mg/dl) | 5.37 | ± | 0.35 |
Serum Creatinine (mg/dl) | 0.76 | ± | 0.02 |
Estimated GFR (ml/min/1.73m2) | 82.4 | ± | 2.3 |
≧30 and < 45, n (%) | 24 | (11.5) | |
≧45 and < 60, n (%) | 23 | (11.0) | |
≧60 and < 90, n (%) | 86 | (41.1) | |
≧90, n (%) | 76 | (36.4) | |
Serum Cystatin C (mg/dl) | 0.90 | ± | 0.02 |
Urinary Albumin (mg/gCr) | 257.6 | ± | 55.7 |
Urinary Albumin (mg/day) | 256.0 | ± | 50.0 |
Treatment | |||
Glucose lowering agents | |||
Insulin, n (%) | 162 | (77.5) | |
Biguanides, n (%) | 59 | (28.2) | |
Sulfonylureas, n (%) | 27 | (12.9) | |
DPP-4 inhibitors, n (%) | 118 | (56.4) | |
GLP-1 R agonists, n (%) | 17 | (8.1) | |
Others, n (%) | 43 | (20.6) | |
Hypertension, n (%) | 109 | (52.2) | |
Antihypertensive agents in subjects with hypertension | |||
Angiotensin-converting enzyme inhibitors, n (%) | 7 | (6.4) | |
Angiotensin receptor blockers, n (%) | 79 | (72.5) | |
Calcium channel blockers, n (%) | 72 | (66.1) | |
Diuretics, n (%) | 33 | (30.3) | |
Alpha-blockers, n (%) | 10 | (9.2) | |
Beta-blockers, n (%) | 5 | (4.6) | |